title: Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer.
abstract: The pharmacokinetics of intraperitoneal doxorubicin in three previously untreated patients with ovarian cancer are described. All patients were maximally cytoreduced (largest residual tumor less than or equal to 2 cm). The average total body clearance (TBC) was 16.3 ml/kg/min (range 10.6-20.4 ml/kg/min) and the mean volume of distribution (VD) was 42.4 liter/kg (range 27.6-46.9 liter/kg). Half-life of elimination (t 1/2 beta) was 2.6 hr. In spite of a therapeutic advantage of 60 when administered intraperitoneally, prohibitive local toxicity limited the use of doxorubicin via the intraperitoneal route in patients with ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Hutzel Hospital, Detroit, Michigan 48201.
authors.forename: V K
authors.initials: VK
authors.lastname: Malviya
authors.forename: G
authors.initials: G
authors.lastname: Deppe
authors.forename: G
authors.initials: G
authors.lastname: Boike
authors.forename: J
authors.initials: J
authors.lastname: Young
mesh_terms: D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010529:Peritoneal Cavity
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin